Significantly variable serum polyunsaturated fatty acid metabolites. by Patrick C. Barko (10668358)

“…Linear mixed-effects models were used to identify serum metabolites that varied significantly among the storage conditions. …”

Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

Significantly variable serum amino acid and gamma-glutamyl amino acid metabolites. by Patrick C. Barko (10668358)

“…Linear mixed-effects models were used to identify serum metabolites that varied significantly among the storage conditions. …”

AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner. by Matthew Drill (22258391)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Intra- and inter-day precision and accuracy. by Ewa Paszkowska (21246702)

“…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …”

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit. by Lisa Thiele (6468056)

Subjects:

The summarized graph for the values of the coefficients of significant linear trends. by Ekaterina Ivanova (230383)

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Significant inter-relationships between baseline variables and MSCC or MCS. by Harshit Arora (22008280)

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Linear regression analysis of changes of E’ and LVGLS with hemodynamic data (N = 29). by Ho-Min Yoon (18310064)

Subjects:

Linear regression analysis of baseline E’ and LVGLS with hemodynamic data (N = 29). by Ho-Min Yoon (18310064)

Subjects:

Hierarchical linear regression models for wave 3 alcohol use frequency. by Karen G. Chartier (11714643)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)